La Jolla, CA, United States of America

Paul R Schimmel

USPTO Granted Patents = 34 


 

Average Co-Inventor Count = 2.2

ph-index = 19

Forward Citations = 1,628(Granted Patents)


Location History:

  • Lexington, MA (US) (1985 - 1991)
  • Cambridge, MA (US) (1997 - 2007)
  • La Jolla, CA (US) (2005 - 2015)

Company Filing History:


Years Active: 1985-2015

Loading Chart...
Loading Chart...
Loading Chart...
34 patents (USPTO):Explore Patents

Title: Innovations in RNA Inhibition: The Contributions of Paul R. Schimmel

Introduction

Paul R. Schimmel, based in Cambridge, MA, is a notable inventor in the field of molecular biology. With 17 patents to his name, his work primarily focuses on innovative methods for targeting ribonucleic acid (RNA) sequences, an area critical for advancements in biomedical research and therapeutic development.

Latest Patents

Schimmel's latest patents include groundbreaking methods for designing compounds that specifically inhibit RNA function. His approach involves targeting short, critical sequences within RNA that are essential for biological function. By utilizing computer modeling, he effectively designs compounds that bind to nucleotide sequences within RNA, taking into account the secondary and tertiary structures associated with the minor groove. This innovative method allows for the synthesis of molecules that possess the necessary chemical characteristics to bind specifically to critical regions of RNA, thereby inhibiting its function. Moreover, his patents encompass modifications to existing molecules known to bind to RNA, enhancing their specificity while reducing potential toxicity.

Career Highlights

Throughout his distinguished career, Schimmel has held positions at prestigious institutions, including the Massachusetts Institute of Technology (MIT) and Cubist Pharmaceuticals Incorporated. His work has significantly contributed to the understanding of RNA functionality and therapeutic intervention strategies.

Collaborations

Schimmel has collaborated with esteemed colleagues such as Kiyotaka Shiba and Mandana Sassanfar. These partnerships have further propelled his research and development in RNA-targeting compounds, leading to innovations that could shape therapeutic approaches for various diseases.

Conclusion

Paul R. Schimmel's pioneering work in RNA inhibition represents a significant advancement in molecular biology. His inventive methods, encapsulated in his numerous patents, provide vital insights and tools for the scientific community, promising to enhance our understanding of RNA and its critical roles in health and disease.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…